What should I know first?

Tobacco use disorder is more than a habit someone could simply abandon by trying harder. It involves a pattern of impaired control and continued use despite significant consequences. Nicotine is central to dependence, while many serious harms of smoking come from other components of tobacco smoke.

Products differ: cigarettes, smokeless tobacco and electronic nicotine products are not interchangeable. ICD-11 uses a nicotine-focused framework, so terminology may differ between records. This article includes relevant nicotine-dependence concepts while making clear which treatment evidence concerns smoking cessation.

Withdrawal and cravings

Cravings, irritability, difficulty concentrating, restlessness and disturbed sleep can occur after stopping. Symptoms tend to be strongest early and usually ease, although timing varies. Strong cravings do not mean someone lacks motivation or that stopping cannot succeed.

Assessment and planning

A stop-smoking discussion considers the products used, previous attempts, cravings, health, medicines and personal priorities. The purpose is to choose useful support, not to require someone to pass a diagnostic test before receiving help.

How Common Is It?

Tobacco exposure is common worldwide, but smoking rates, nicotine-product use and diagnosable tobacco use disorder are different measures. Estimates vary by age, country, product and assessment method. A survey of cigarette smoking cannot fully describe vaping-related dependence or all nicotine use.

Likewise, disease and death statistics describe the consequences of exposure rather than the prevalence of the psychiatric diagnosis. This article therefore avoids assigning one universal percentage to the disorder. The clinically useful question is how a person's pattern affects control, health and daily life.

What Causes It?

Nicotine's reinforcing effects interact with routines, stress, social surroundings, product availability and marketing. Repeated use can link everyday cues, such as breaks or social situations, with strong urges. Younger people may be particularly vulnerable to developing dependence. Distress and mental health difficulties can make stopping harder, while inadequate access to treatment can prolong exposure.

These influences explain why support matters; they do not mean a person lacks character or cannot change. Treatment explores both the physical pull of nicotine and the situations that maintain use.

What Do We Know About the Brain?

Nicotine affects brain processes involved in reward, attention and arousal. With repeated exposure, the brain adapts, and stopping can temporarily disrupt concentration, mood and comfort. Learned cues can continue to prompt urges even after the most immediate withdrawal has eased.

This helps explain why repeated attempts may be necessary and why both medicines and behavioural support can help. Brain science does not provide a routine scan for diagnosing the disorder. Recovery also depends on environmental changes and accessible support, not only on understanding biological adaptation.

Conditions With Similar Symptoms

Withdrawal can resemble anxiety, low mood, sleep disturbance or attention difficulties. Those symptoms should be considered in relation to changes in nicotine use without assuming that every symptom is temporary withdrawal. Independent psychiatric and medical conditions may also need care.

Nicotine poisoning after an unintended exposure is an acute medical problem, not evidence of a chronic use disorder. The health effects of tobacco smoke are also distinct from nicotine dependence, even though they are closely related. Identifying the product helps prevent misleading comparisons between these problems.

Other Conditions That Can Occur Together

Depression, anxiety and other substance use disorders can occur with tobacco use disorder. Smoking-related lung, cardiovascular and other diseases may also shape treatment needs. These conditions should be addressed together rather than requiring mental health symptoms to disappear before cessation support is offered.

People taking medicines or receiving care for pregnancy or other medical circumstances should discuss their cessation plan with a clinician. The goal is to select appropriate support and follow-up, not to assume that one product or medicine is suitable for everyone.

UK stop-smoking support

Behavioural support can be combined with an appropriate treatment. NICE discusses nicotine replacement, varenicline, cytisinicline, bupropion and nicotine-containing e-cigarettes as options within its recommendations. Age, pregnancy, medical suitability and local access matter; this is not a recommendation for a particular individual.

Medicines and product distinctions

Nicotine replacement supplies nicotine without tobacco smoke and may combine a longer-acting with a shorter-acting product. Prescribed nicotine-free medicines have different contraindications and treatment courses. Vapes are not interchangeable with licensed medicines, and long-term risks should not be described as absent.

For tobacco-dependent young people aged 12 and over, NICE says nicotine replacement may be considered with behavioural support. Do not offer varenicline, bupropion or cytisinicline to under-18s. These age-specific recommendations must remain separate from the adult list of treatment options.

What to Expect Over Time

Many people make more than one attempt before maintaining change. A return to use can reveal a trigger or support gap, not prove that treatment has failed permanently. Withdrawal and urges may change over time, and follow-up can help adjust the plan.

Improvements in health can occur after smoking stops, while established illnesses may still require ongoing care. Progress should include reduced harm and increased control, with honest discussion of continued exposure. No single timetable describes every person's recovery or the improvement of every smoking-related health problem.

Everyday support

Agree practical help from others, identify smoking triggers and build activities that do not revolve around tobacco. People receiving mental healthcare should be offered support, not assumed incapable of stopping. Discuss prescribed medicines with the treatment team as smoking changes.

Pregnancy and younger people

NICE advises against cytisinicline, varenicline or bupropion in pregnancy or breastfeeding. Pregnancy support may involve nicotine replacement with behavioural help after a clinical discussion. Adult treatment recommendations should not be applied automatically to children.

History and terminology

Tobacco's cultural and commercial history predates recognition of its full health burden. Older clinical records commonly use nicotine dependence, while DSM uses tobacco use disorder and ICD-11 organises relevant categories around nicotine. These labels should be interpreted alongside the actual product.

UK cessation care now includes behavioural support and several treatment options; the NICE recommendations distinguish medicines and nicotine-containing e-cigarettes rather than treating them as interchangeable regulated products. Less harmful than smoking does not mean risk-free.

Sources and References

  1. Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders (2024)

    Scope: International scientific background; not UK prescribing or healthcare guidance.

  2. The Relative Risks of Tobacco Products

    Scope: International scientific background; not UK prescribing or healthcare guidance.

  3. What Is a Substance Use Disorder? (physician review 2024-04)

    Scope: International scientific background; not UK prescribing or healthcare guidance.

  4. Want to Quit Smoking? FDA-Approved and FDA-Cleared Cessation Products Can Help

    Scope: International scientific background; not UK prescribing or healthcare guidance.

  5. Managing nicotine withdrawal symptoms

    Scope: United Kingdom; service delivery may differ by nation.

  6. Tobacco: treating tobacco dependence

    Scope: United Kingdom; NICE recommendations require attention to national implementation and local pathways.

  7. Tobacco dependence during pregnancy and after childbirth

    Scope: NICE maternity guidance.

  8. The truth about smoking, stress and mental health

    Scope: England public health information.

  9. Highlights of Changes from DSM-IV-TR to DSM-5 (2013)

    Scope: International explanatory background; not UK prescribing or service guidance.

  10. Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top